Equity Overview
Price & Market Data
Price: $1.34
Daily Change: -$0.06 / 4.48%
Range: $1.28 - $1.39
Market Cap: $21,826,284
Volume: 315,822
Performance Metrics
1 Week: -7.19%
1 Month: 3.20%
3 Months: 32.99%
6 Months: 0.78%
1 Year: 65.36%
YTD: 13.16%
Company Details
Employees: 5
Sector: Health technology
Industry: Pharmaceuticals: other
Country: United States
Details
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.